Selective inhibition of IDO1, D-1-methyl-tryptophan (D-1MT), effectively increased EpCAM/CD3-bispecific BiTE antibody MT110 efficacy against IDO1breast cancer via enhancing immune cells activity.

MuS110 and MT110 are BiTE antibodies bispecific for CD3 and EpCAM, which is the most frequently and highly expressed tumor-associated antigen on breast cancer. And pronounced expression of IDO1 has also been reported in breast cancer. Our study aimed to investigate whether IDO1 inhibitor D-1MT combing with MuS110/MT110 had synergistic antitumor effects on IDO expressing EpCAM-positive breast cancer cells in vitro and in vivo.

[Sexual function and sexual life quality of chronic prostatitis patients: a clinical investigation].

Objective: To investigate the sexual function and the quality of sexual life in patients with chronic prostatitis (CP), and to analyze the correlated factors and their influence on the quality of life (QOL) of the CP patients.

Methods: We randomly selected 148 CP patients as the CP group and 71 healthy men as controls, asked them to fill out a questionnaire on sexual function and the quality of sexual life, obtained their scores on NHI-CPSI, and comparatively analyzed the results. We also made analyses on the influence of age, disease course, CP symptom scores and EPS level on sexual function and the quality of sexual life, as well as the impact of CP symptoms, sexual dysfunction and sexual life quality on the QOL of the CP patients.